28284173|t|Patient - derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour
28284173|a|Preclinical models that mimic pathological and molecular features of solitary fibrous tumour (SFT) represent an important tool to select effective regimes and novel compounds to be tested in the clinic. This study was aimed at developing two preclinical models of SFT, assessing their predictive value in the clinic and selecting potential novel effective treatments. Two dedifferentiated-SFT (D-SFT) models obtained from patients ' biopsies were grown in immunodeficient mice. The antitumour activity on these models of doxorubicin, dacarbazine (DTIC), ifosfamide (monotherapy or combination), trabectedin and eribulin was tested. Twelve SFT patients were treated with doxorubicin and DTIC. Response by RECIST, progression-free survival and overall survival were retrospectively evaluated, distinguishing malignant-SFT (M-SFT) and D-SFT. Two D-SFT patient-derived xenografts (PDXs) that represent the first available preclinical in vivo models of SFT were developed and characterised. Doxorubicin/DTIC, DTIC/ifosfamide, doxorubicin/ifosfamide combinations consistently induced better antitumour activity than the single-agents. Particularly, doxorubicin/DTIC combination caused a max tumour volume inhibition >80% in both models. Doxorubicin/DTIC combo showed activity also in the case-series. Best RECIST responses were: 6 responses (M-SFT = 2 of 7, D-SFT = 4 of 5), 1 stable disease, 5 progressions, with a 6-month median progression-free survival (M-SFT = 6, D-SFT = 10 months). The PDXs were very sensitive to trabectedin and eribulin. Doxorubicin plus DTIC combination was effective in our two D-SFT mice models and appeared to be active also in the clinic, especially in high-grade D-SFT patients. Among additional drugs tested in the PDXs, trabectedin and eribulin were highly effective, providing a rational to test these drugs in D-SFT patients.
28284173	0	7	Patient	T101	C0030705
28284173	10	17	derived	T080	C1441547
28284173	18	41	solitary fibrous tumour	T191	C1266119
28284173	42	52	xenografts	T122	C0522537
28284173	53	60	predict	T078	C0681842
28284173	61	65	high	T080	C0205250
28284173	66	77	sensitivity	T081	C1511883
28284173	81	116	doxorubicin/dacarbazine combination	T061	C0050841
28284173	117	126	confirmed	T080	C0521093
28284173	134	140	clinic	T073,T093	C0442592
28284173	159	168	potential	T080	C3245505
28284173	169	182	effectiveness	T080	C1280519
28284173	186	197	trabectedin	T109,T121	C1311070
28284173	201	209	eribulin	T109,T121	C2350866
28284173	210	217	against	T080	C0521124
28284173	223	229	tumour	T191	C0027651
28284173	230	248	Preclinical models	T170	C1514292
28284173	260	272	pathological	T169	C1521733
28284173	277	286	molecular	T167	C0567416
28284173	287	295	features	T080	C2348519
28284173	299	322	solitary fibrous tumour	T191	C1266119
28284173	324	327	SFT	T191	C1266119
28284173	329	338	represent	T052	C1882932
28284173	342	351	important	T080	C3898777
28284173	352	356	tool	T170	C1516602
28284173	360	366	select	T052	C1707391
28284173	367	376	effective	T080	C1704419
28284173	377	384	regimes	T058	C0418956
28284173	389	394	novel	T080	C0205314
28284173	395	404	compounds	T080	C0205198
28284173	411	417	tested	T169	C0039593
28284173	425	431	clinic	T073,T093	C0442592
28284173	438	443	study	T062	C2603343
28284173	448	453	aimed	T169	C1521840
28284173	472	490	preclinical models	T170	C1514292
28284173	494	497	SFT	T191	C1266119
28284173	515	531	predictive value	T080	C1514307
28284173	539	545	clinic	T073,T093	C0442592
28284173	550	559	selecting	T052	C1707391
28284173	560	569	potential	T080	C3245505
28284173	570	575	novel	T080	C0205314
28284173	576	585	effective	T080	C1704419
28284173	586	596	treatments	T169	C1522326
28284173	602	622	dedifferentiated-SFT	T191	C2699572
28284173	624	629	D-SFT	T191	C2699572
28284173	631	637	models	T170	C1514292
28284173	638	646	obtained	T169	C1301820
28284173	652	660	patients	T101	C0030705
28284173	663	671	biopsies	T060	C0005558
28284173	686	706	immunodeficient mice	T015	C1512658
28284173	712	731	antitumour activity	T033	C0243095
28284173	741	747	models	T170	C1514292
28284173	751	762	doxorubicin	T109,T195	C0013089
28284173	764	775	dacarbazine	T109,T121	C0010927
28284173	777	781	DTIC	T109,T121	C0010927
28284173	784	794	ifosfamide	T109,T121	C0020823
28284173	796	807	monotherapy	T061	C3846440
28284173	811	822	combination	T061	C0013218
28284173	825	836	trabectedin	T109,T121	C1311070
28284173	841	849	eribulin	T109,T121	C2350866
28284173	854	860	tested	T169	C0039593
28284173	869	872	SFT	T191	C1266119
28284173	873	881	patients	T101	C0030705
28284173	887	899	treated with	T061	C0332293
28284173	900	911	doxorubicin	T109,T195	C0013089
28284173	916	920	DTIC	T109,T121	C0010927
28284173	922	930	Response	T032	C0871261
28284173	934	940	RECIST	T170	C1709926
28284173	942	967	progression-free survival	T081	C0242792
28284173	972	988	overall survival	T081	C4086681
28284173	994	1009	retrospectively	T080	C1514923
28284173	1021	1035	distinguishing	T080	C0205615
28284173	1036	1049	malignant-SFT	T191	C1266120
28284173	1051	1056	M-SFT	T191	C1266120
28284173	1062	1067	D-SFT	T191	C2699572
28284173	1073	1078	D-SFT	T191	C2699572
28284173	1079	1105	patient-derived xenografts	T050	C4050317
28284173	1107	1111	PDXs	T050	C4050317
28284173	1148	1159	preclinical	T080	C1709630
28284173	1160	1174	in vivo models	T062	C1515657
28284173	1178	1181	SFT	T191	C1266119
28284173	1201	1214	characterised	T052	C1880022
28284173	1216	1232	Doxorubicin/DTIC	T061	C0050841
28284173	1234	1249	DTIC/ifosfamide	T061	C0013218
28284173	1251	1286	doxorubicin/ifosfamide combinations	T061	C0278906
28284173	1300	1307	induced	T169	C0205263
28284173	1308	1314	better	T080	C0332272
28284173	1315	1334	antitumour activity	T033	C0243095
28284173	1344	1357	single-agents	T061	C3846440
28284173	1373	1401	doxorubicin/DTIC combination	T061	C0050841
28284173	1402	1408	caused	T169	C0015127
28284173	1411	1414	max	T081	C0806909
28284173	1415	1439	tumour volume inhibition	T043	C1512773
28284173	1448	1452	both	T080	C1706086
28284173	1453	1459	models	T170	C1514292
28284173	1461	1483	Doxorubicin/DTIC combo	T061	C0050841
28284173	1491	1499	activity	T169	C0205177
28284173	1512	1523	case-series	T062	C0150093
28284173	1530	1536	RECIST	T170	C1709926
28284173	1537	1546	responses	T032	C0871261
28284173	1555	1564	responses	T032	C0871261
28284173	1566	1571	M-SFT	T191	C1266120
28284173	1582	1587	D-SFT	T191	C2699572
28284173	1601	1615	stable disease	T033	C0677946
28284173	1619	1631	progressions	T046	C0242656
28284173	1640	1647	6-month	T079	C0439231
28284173	1655	1680	progression-free survival	T081	C0242792
28284173	1682	1687	M-SFT	T191	C1266120
28284173	1693	1698	D-SFT	T191	C2699572
28284173	1701	1710	10 months	T079	C0439231
28284173	1717	1721	PDXs	T050	C4050317
28284173	1732	1741	sensitive	T169	C0332324
28284173	1745	1756	trabectedin	T109,T121	C1311070
28284173	1761	1769	eribulin	T109,T121	C2350866
28284173	1771	1804	Doxorubicin plus DTIC combination	T061	C0050841
28284173	1809	1818	effective	T080	C1704419
28284173	1830	1835	D-SFT	T191	C2699572
28284173	1836	1847	mice models	T170	C0086272
28284173	1852	1860	appeared	T080	C0700364
28284173	1867	1873	active	T169	C0205177
28284173	1886	1892	clinic	T073,T093	C0442592
28284173	1908	1918	high-grade	T080	C0205082
28284173	1919	1924	D-SFT	T191	C2699572
28284173	1925	1933	patients	T101	C0030705
28284173	1941	1951	additional	T169	C1524062
28284173	1952	1957	drugs	T121	C0013227
28284173	1958	1964	tested	T169	C0039593
28284173	1972	1976	PDXs	T050	C4050317
28284173	1978	1989	trabectedin	T109,T121	C1311070
28284173	1994	2002	eribulin	T109,T121	C2350866
28284173	2008	2014	highly	T080	C0205250
28284173	2015	2024	effective	T080	C1704419
28284173	2050	2054	test	T169	C0039593
28284173	2061	2066	drugs	T121	C0013227
28284173	2070	2075	D-SFT	T191	C2699572
28284173	2076	2084	patients	T101	C0030705